| 9.45 0.12 (1.29%) | 03-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 12.05 | 1-year : | 14.07 |
| Resists | First : | 10.31 | Second : | 12.05 |
| Pivot price | 9.21 |
|||
| Supports | First : | 8.55 |
Second : | 7.46 |
| MAs | MA(5) : | 9.47  |
MA(20) : | 9.05 |
| MA(100) : | 7.57 |
MA(250) : | 8.14 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 59.7 |
D(3) : | 60.9 |
| RSI | RSI(14): 62.2 |
|||
| 52-week | High : | 11.31 | Low : | 6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BCRX ] has closed below upper band by 38.3%. Bollinger Bands are 63% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.53 - 9.6 | 9.6 - 9.65 |
| Low: | 9.05 - 9.12 | 9.12 - 9.17 |
| Close: | 9.36 - 9.47 | 9.47 - 9.55 |
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Tue, 31 Mar 2026
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Mon, 30 Mar 2026
BioCryst (BCRX) rallies 7.10% on acquisition buzz - MSN
Mon, 30 Mar 2026
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by JPMorgan Chase & Co. - MarketBeat
Sun, 29 Mar 2026
BioCryst stock jumps after hours on big pharma suitor buzz — retail sentiment hits 2026 peak - MSN
Thu, 26 Mar 2026
Vanguard amends Schedule 13G — BioCryst (BCRX) ownership shown as 0 - Stock Titan
Thu, 26 Mar 2026
Does BioCryst Pharmaceuticals (BCRX) Still Offer Value After Recent Share Price Strength? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 251 (M) |
| Shares Float | 218 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 85.2 (%) |
| Shares Short | 37,480 (K) |
| Shares Short P.Month | 40,320 (K) |
| EPS | 1.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.57 |
| Profit Margin | 30.1 % |
| Operating Margin | 65.5 % |
| Return on Assets (ttm) | 43.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 209.1 % |
| Gross Profit (p.s.) | 2.75 |
| Sales Per Share | 3.48 |
| EBITDA (p.s.) | 1.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 347 (M) |
| Levered Free Cash Flow | 256 (M) |
| PE Ratio | 7.8 |
| PEG Ratio | 0 |
| Price to Book value | -16.88 |
| Price to Sales | 2.7 |
| Price to Cash Flow | 6.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|